Navigation Links
Nautilus Neurosciences Announces New Patent Issued
Date:2/1/2012

BEDMINSTER, N.J., Feb. 1, 2012 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in Bedminster, New Jersey, announced today that United States Patent and Trademark Office has issued U.S. Patent 8,097,651 entitled "Diclofenac formulations and methods of use." This patent relates to methods and formulations for treating migraine. Additionally, methods are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting. The patent provides additional protection for Cambia™, Nautilus' marketed product for the treatment of migraine through June 2026. This patent was licensed to Nautilus for Cambia™ in the North American markets by the Swiss company APR Applied Pharma Research, and is now listed in the FDA's Orange Book.

This coverage is in addition to that provided by U.S. Patent Nos. 7,759,394; 7,482,377; and 6,974,595.

About CAMBIA™

Nautilus' lead product, CAMBIA™, is a novel treatment for acute migraine in adults. CAMBIA is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine. Engineered using Dynamic Buffering Technology (DBT), CAMBIA is specifically designed for fast, effective relief from the symptoms of migraine. Designed to treat the underlying pathophysiology of migraine, Cambia reaches peak blood levels within 15 minutes and has been proven to provide equally as rapid relief in migraine. The FDA approval of CAMBIA was based on two Phase 3 placebo-controlled trials showing that CAMBIA was superior to placebo in all four FDA-mandated co-primary end points for migraine -- pain, nausea, photophobia and phonophobia. Both studies also showed that reduction in pain intensity was significantly greater in the CAMBIA group than in the placebo group as early as 15 minutes following treatment, and headache response rates were superior to placebo for up to 24 hours.

Nautilus Neurosciences, Inc.

Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the health care community with medically relevant products and services that directly benefit those affected by neurologic disorders. Nautilus is sponsored by Tailwind Capital and Galen Partners.

CONTACT: 
William Maichle
Chief Executive Officer
Nautilus Neurosciences, Inc.
908-393-7800
WMaichle@nautilusneurosciences.com

 

 


'/>"/>
SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
2. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
3. Intellect Neurosciences, Inc. to Present at BIO Asia International Conference
4. Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
5. Intellect Neurosciences, Inc. to Present at OneMedForum
6. Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimers Immunotherapy Programs
7. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimers Patent Application
8. Intellect Neurosciences Announces Its New CONJUMAB-A Platform Technology for Novel Treatments of Alzheimers Disease and Other Proteinopathies
9. Intellect Neurosciences Issues Letter to Shareholders
10. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
11. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... 1, 2017 Michael Penna , President ... highlights opportunities for growth in his response to the ... Equity is seeking a buyer for eMDs. Penna,s company, ... healthcare solutions Value Added Reseller and national leader in ... "As the healthcare market continues to dictate ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/29/2017)... Va. , Aug. 29, 2017 ivWatch, LLC, the ... peripheral IV infiltrations, announced it has been awarded an Innovative Technology ... company in the country. ... continuous monitoring device to aid in the early detection of peripheral ... The Innovative ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare and Medicaid Services ... will transition to using only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated ... 60-minute complimentary webinars on October 17, 2017 at 2 P.M. EST and ...
(Date:9/20/2017)... ... 2017 , ... Recognising that in today’s busy world consumers ... positive results in just three weeks. Setting the groundwork for a healthier lifestyle, ... into hectic work and family schedules, participants can lose up to 15lbs during ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story ... average life. This mouse sets out on a journey that will show that friends ... the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a ...
(Date:9/20/2017)... ... ... “Psalms of Humidity”: is a fascinating depiction of daily struggles and the ... closer to God. “Psalms of Humidity” is the creation of published author, David Waldrop, ... his life are the very same things that have shaped him into the man ...
(Date:9/20/2017)... ... 20, 2017 , ... “They Sang At Her Funeral”: a tale of murder ... the skeletons in their closets. “They Sang At Her Funeral” is the creation of ... and married with five children and twelve grandchildren. Before becoming a writer, Annalise had ...
Breaking Medicine News(10 mins):